NangioTx, Inc. Named “Best in Show” at Mid-Atlantic Bio Angels 1st Pitch Life Science Competition, Co-Founded by Partner Stephen M. Goodman
Mid-Atlantic Bio Angels (MABA), an angel investor group focused on early-stage life science companies, announced that NangioTx, Inc. was voted as “Best in Show” at the first of MABA's 1st Pitch Life Science events of 2016, which took place at the Civic Hall in New York City on February 23, 2016. Partner Stephen M. Goodman is a co-founder of MABA.
"As evidenced by the generally positive comments from the panel, NangioTx co-founder Vivek Kumar concisely articulated the medical issue and the proposed solution, provided enough data to give substance to the company's hypothesis and set out a reasonable path to market, without minimizing potential issues. A well-deserved win," commented Goodman.
NangioTx is a Houston-based drug development company developing a novel drug promoting growth of new blood vessels in the muscles of patients with peripheral artery disease, which causes muscle atrophy and cell death.
